COMP <GO>
MRK vs JNJ // RETURN ON INVESTED CAPITAL (ROIC)
Merck & Company Inc. Common Stock (new) (NYSE) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: MRK 6
— JNJ 9
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: JNJ
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
roic
20.70%
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
roic
25.50%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MRK VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MRK | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 74.80% | 67.90% | +6.90 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | 20.70% | 25.50% | -4.80 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 15.3x | 18.5x | -3.20 | MRK | /valuation <GO> |
| Free Cash Flow Yield | 3.42% | 2.97% | +0.45 | MRK | /fcf-yield <GO> |
| Operating Margin | 34.30% | 34.70% | -0.40 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 28.10% | 28.50% | -0.40 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 1.30% | 6.00% | -4.70 | JNJ | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 2.26% | 0.00% | +2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.19 | 5.59 | -0.40 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 8/9 | -1.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.60% | 7.20% | -0.60 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 56.9 | 60.4 | -3.49 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.92 | 1.08 | -0.16 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 18.4x | 23.0x | -4.60 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $361.02B | $662.49B | -$301.47B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MRK REV | JNJ REV | MRK GROSS % | JNJ GROSS % | MRK FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $65.01B | $94.19B | 74.8% | 67.9% | $12.36B | $19.70B |
| FY 2024 | $64.17B | $88.82B | 76.3% | 69.1% | $18.10B | $19.84B |
| FY 2023 | $60.12B | $85.16B | 44.0% | 44.0% | $10.30B | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MRK // BETA 0.92
JNJ // BETA 1.08